Pharmaceutical

SPRIM PRO and ObvioHealth Expand Collaboration to Deliver Digitally Enabled Trials with Scientific Rigor and Global Reach

NEW YORK, July 15, 2025 /PRNewswire/ -- SPRIM PRO and ObvioHealth, sister companies within the SPRIM Group, have expanded their…

5 months ago

Immorta Bio, a Scientific Longevity Company, Appoints Pharmaceutical Industry Veteran Dr. Armin Rath as Chief Business Officer

Senolytic Immunotherapy Leader Expands Executive Team in Anticipation of Clinical Trial Launch MIAMI BEACH, Fla., July 15, 2025 /PRNewswire/ --…

5 months ago

Alliance Pharmaceuticals Ltd Partners with TrueMed to Combat Sophisticated Counterfeits with AI-Powered Authentication

New collaboration brings faster, digital-first counterfeit detection to the front lines of pharmaceutical brand protection. HELSINKI, July 15, 2025 /PRNewswire/…

5 months ago

EVERSANA Announces Enterprise Advancement to ‘Pharmatize AI” With the Launch of the EVERSANA AI Accelerator

CHICAGO, July 15, 2025 /PRNewswire/ -- EVERSANA®, a leading provider of commercialization services to the global life sciences industry, today…

5 months ago

Virtusa Named a Major Contender in Everest Group Life Sciences Digital Services PEAK Matrix® Assessment 2025

Recognized for strengthening digital capabilities across the Life Sciences value chainSOUTHBOROUGH, Mass., July 15, 2025 /PRNewswire/ -- Virtusa Corporation, a global…

5 months ago

Evestia Clinical to merge with Atlantic Research Group

Kester Capital-backed Evestia Clinical merges with US-based Atlantic Research Group (ARG) to create a leading independent global specialist CRO in…

6 months ago

Predictive Oncology Issues Shareholder Letter: Well Financed to Support Expanded U.S. Availability and E.U. Launch of ChemoFx® and Pursuit of Other High-Value AI-Driven Drug Discovery and Development Opportunities

$10 million securities purchase agreement provides efficient and flexible funding in support of strategic multi-million dollar growth initiatives Discussions underway…

6 months ago

BiomX Announces Successful Initiation of Phase 2b Trial with First Patient Dosed in BX004 Program in Patients with Cystic Fibrosis

First patient dosing in Company’s Phase 2b trial marks pivotal milestone in phage therapy development program targeting antibiotic-resistant lung infections…

6 months ago

Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™

Payer coverage for Emrosi™ now available for 65% of commercial lives, up from 29% in May 2025 Expanding payer coverage…

6 months ago

Disc Medicine Appoints Nadim Ahmed to its Board of Directors

WATERTOWN, Mass., July 14, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery,…

6 months ago